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Acute myeloblastic leukemia in adult patients: ESMO
Clinical Recommendations for diagnosis, treatment and
follow-up
incidence
The crude incidence of acute myeloblastic leukemia (AML)
in adults in Europe is 5–8 cases/100 000/year. The mortality
is 4–6 cases/100 000/year.
diagnosis
The diagnosis of AML requires examination of peripheral
blood and bone marrow samples. Work-up should
comprise morphological examination, cytochemistry,
immunophenotyping, cytogenetic and selected molecular
analysis.
risk assessment
Risk assessment in AML includes the patient’s age, the initial
leukocyte count, the AML subtype, karyotype data and selected
molecular markers. AML with the chromosomal translocations
t(15;17) [acute promyelocytic leukemia (APL)], t(8;21) and
t(16;16) (including acute myelomonocytic leukemia with
preponderance of eosinophil granulocytes) are considered as
favorable [II, A]. An antecedent or concomitant myelodysplastic
syndrome or complex aberrant karyotypes are adverse
prognostic factors. Preexisting medical conditions such as
diabetes or coronary heart disease may affect the feasibility of
intensive chemotherapy. Elderly patients have an adverse
prognosis and are more susceptible to treatment complications.
If an infection is suspected, a thoracic computed tomography
(CT) scan and an abdominal ultrasound or a CT scan may be
performed to assess lung, liver, spleen, lymph nodes and kidneys
for possible pathological alterations. Cardiac examination
including echocardiography is recommended for patients with
cardiac risk factors or a history of heart disease [A].
In addition to hematological and chemistry tests,
a coagulation screening is to be performed before the insertion
of central venous lines. Human leukocyte antigen (HLA)
typing of patients and their family members identifies patients
who are candidates for an allogeneic bone marrow or stem-cell
transplants [A].
treatment plan
Treatment is divided into induction and consolidation
chemotherapy. Whenever possible it should be planned with
a curative intent. Candidates for allogeneic stem-cell
transplantation should be identified early during induction.
Patients with poor performance status and considerable
comorbidity, as well as elderly patients not eligible for curative
treatment, should receive supportive care. Whenever possible
AML treatment should be in clinical trials and in centers
offering a multidisciplinary approach. Such centers should
provide an adequate infrastructure including a full
hematology and medical oncology service, a close collaboration
with a bone marrow transplant unit, as well as an infectious
disease service and an adequate transfusion service.
induction chemotherapy
Chemotherapy should be postponed until all material
satisfactory for diagnostic tests has been harvested. Patients with
excessive leukocytosis at presentation may require emergency
leukapheresis before induction chemotherapy. Especially in
these patients with high leukocyte counts, adequate measures
should be taken to avoid tumor lysis syndrome during the first
days of treatment (including a prephase if appropriate).
Induction chemotherapy should include an anthracycline and
cytarabine [II, A]. Patients failing to respond to one to two
cycles of such treatment are considered refractory. APL
induction chemotherapy should be complemented with
all-trans retinoic acid (ATRA) [II, A]. Hematopoietic growth
factors are an optional adjunct to intensive chemotherapy.
consolidation therapy
Patients entering clinical and hematological remission should
receive one to several cycles of postremission therapy [II, A].
There is no consensus on a single ‘best’ postremission treatment
strategy. Patients with good risk features as defined above
should receive chemotherapy only, preferably with high-dose
cytarabine. All other patients with an HLA-identical sibling
are candidates for allogeneic stem-cell transplantation in first
remission [III, A]. Patients with particular poor risk features and
no donor in the family may qualify for an allogeneic transplant
with an unrelated matched donor [III, A]. The role of prolonged
monthly maintenance or high-dose consolidation
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chemotherapy with autologous peripheral stem-cell support
in AML is controversial. Maintenance chemotherapy and
ATRA are beneficial in APL [III, A].
therapy of relapsed or refractory
patients
Patients in second or subsequent remission may qualify for
allogeneic transplantation with an unrelated HLA-matched
donor. In relapsed APL, arsenic trioxide can induce remission
even if patients have become refractory to ATRA [III, B].
response evaluation
Response to induction is monitored through clinical
examination, serial peripheral blood counts and bone marrow
aspirates. During induction-induced aplasia, a bone marrow
aspirate should be obtained to monitor for early marrow
response or leukemic blast persistence. The usual requirements
of AML remission are a normal cellularity of the bone marrow,
blast levels <5% in bone marrow smears and morphologically
normal hematopoiesis [B].
follow-up
Patients are followed clinically and with hematological
examinations to detect early relapse. Serial bone marrow
examination is of uncertain value in remission patients without
any clinical or hematological evidence of relapse.
note
Levels of evidence [I–V] and grades of recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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